Not provided
Not provided
Not provided
Not provided
Not provided
There was no indication that long-term follow-up would differ between any of the studies that have evaluated devices within the 410 Style Matrix.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is a prospective, multicenter, nonrandomized study to provide access to and evaluate the safety and effectiveness of NATRELLE® 410 Highly Cohesive Anatomically Shaped Silicone-Filled X-Style and L-Style Breast Implants for breast augmentation, reconstruction, or revision.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Augmentation | Experimental | Women who had breast augmentation with NATRELLE® 410 implants. |
|
| Reconstruction | Experimental | Women who had breast reconstruction with NATRELLE® 410 implants. |
|
| Revision-Augmentation | Experimental | Women who had revision of previous breast augmentation with NATRELLE® 410 implants. |
|
| Revision-Reconstruction | Experimental | Women who had revision of previous breast reconstruction with NATRELLE® 410 implants. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Anatomically shaped, silicone-filled breast implants with low height/projection or extra-full projection | Device | Surgical implant |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants According to Investigator Satisfaction With Implants | The investigator rated their satisfaction with the participant's breast implant for each breast on a 5-point scale (1=Definitely dissatisfied, 2=Somewhat dissatisfied, 3=Neither satisfied or dissatisfied, 4=Somewhat satisfied, 5=Definitely satisfied). If there was a different response for the left and right breasts the worst response was used. The percentage of participants where the investigator responded: "Definitely satisfied" or "Somewhat satisfied" is reported. | 5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015) |
| Percentage of Participants According to Participant Satisfaction With Implants | The participant rated their satisfaction with the breast implant for each breast on a 5-point scale (1=Definitely dissatisfied, 2=Somewhat dissatisfied, 3=Neither satisfied or dissatisfied, 4=Somewhat satisfied, 5=Definitely satisfied). If there was a different response for the left and right breasts the worst response was used. The percentage of participants who responded: "Definitely satisfied" or "Somewhat satisfied" is reported. | 5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015) |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With Local Complications | Kaplan-Meier risk rates (estimation of the percentage of participants) of developing local complications is presented. Local complications collected in the study were: Asymmetry, Breast pain, Capsular contracture, Delayed wound healing, Fluid accumulation/seroma, Hematoma, Hypertrophic scarring/other abnormal scarring, Implant extrusion, Implant malposition, Implant palpability/visibility, Implant rupture, Infection, Redness, Skin rash, Swelling, Tissue/skin necrosis, Upper pole fullness, Wrinkling/rippling and Other complications . |
Not provided
Inclusion Criteria:
For entry in this study, participants must have either been enrolled in the 410 CA Clinical Study or 410 CARE Clinical Study under the inclusion criteria below and received NATRELLE® 410 Highly Cohesive Anatomically Shaped Silicone-Filled X- or L-Style Breast Implants in 1 or both breasts; or be planning to be implanted with NATRELLE® 410 Highly Cohesive Anatomically Shaped Silicone-Filled X- or L-Style Breast Implants in 1 or both breasts and meet the inclusion criteria listed below:
Female, age 18 or older (age 22 or older for breast augmentation participants who are implanted under Protocol 410CAXL-001)
Present with 1 or more of the following conditions:
Has adequate tissue available to cover implants
Exclusion Criteria:
For entry in this study, participants must have either been enrolled in the 410 CA Clinical Study or 410 CARE Clinical Study and did not meet the exclusion criteria listed below or plan to undergo implantation with NATRELLE® 410 Highly Cohesive Anatomically Shaped Silicone-Filled X- or L-Style Breast Implants in 1 or both breasts and does not meet the exclusion criteria listed below:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Andrew Schumacher | Allergan | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Anthony Griffin | Beverly Hills | California | 90211 | United States | ||
| Laurence Berkowitz |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Augmentation | Women who had breast augmentation with NATRELLE® 410 implants. |
| FG001 | Revision-Augmentation | Women who had revision of previous breast augmentation with NATRELLE® 410 implants. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015) |
| Percentage of Participants With Reoperations | Kaplan-Meier risk rates (estimation of the percentage of participants) of reoperation is reported. | 5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015) |
| Percentage of Participants With Implant Removal With or Without Replacement | Kaplan-Meier risk rates (estimation of the percentage of participants) of implant removal with or without replacement is reported. | 5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015) |
| Campbell |
| California |
| 95008 |
| United States |
| Mary Powers | Long Beach | California | 90806 | United States |
| Roy Hong | Palo Alto | California | 94301 | United States |
| Eric Bachelor | Pleasanton | California | 94566 | United States |
| Douglas Reavie | San Diego | California | 92128 | United States |
| Steven Teitelbaum | Santa Monica | California | 90404 | United States |
| Tad Heinz | Colorado Springs | Colorado | 80909 | United States |
| Gary Snider | Denver | Colorado | 80218 | United States |
| Terrence Murphy | Englewood | Colorado | 80113 | United States |
| Orlando De Lucia | Farmington | Connecticut | 06032 | United States |
| Lewis Berger | Tampa | Florida | 33607 | United States |
| Gerard Mosiello | Tampa | Florida | 33647 | United States |
| James Namnoum | Atlanta | Georgia | 30342 | United States |
| Peter Johnson | Des Plaines | Illinois | 60016 | United States |
| Stephen Madry | Elk Grove Village | Illinois | 60007 | United States |
| Janet Turkle | Carmel | Indiana | 46290 | United States |
| Bruce Van Natta | Indianapolis | Indiana | 46290 | United States |
| Christine Kelley-Patteson | Indianapolis | Indiana | 46290 | United States |
| Brad Storm | Olathe | Kansas | 66061 | United States |
| Julene Samuels | Louisville | Kentucky | 40241 | United States |
| Timothy Mickel | Monroe | Louisiana | 71201 | United States |
| Paul Davis | Shreveport | Louisiana | 71105 | United States |
| Bradley Bengtson | Grand Rapids | Michigan | 49503 | United States |
| John Renucci | Grand Rapids | Michigan | 49503 | United States |
| Steven Morris | Midland | Michigan | 48640 | United States |
| Charles Nathan | Chesterfield | Missouri | 63005 | United States |
| Herluf Lund Jr. | Chesterfield | Missouri | 63005 | United States |
| Patricia McGuire | Creve Coeur | Missouri | 63141 | United States |
| Schuyler Meltis | Hannibal | Missouri | 63401 | United States |
| Perry Johnson | Omaha | Nebraska | 68102 | United States |
| Perry Johnson | Omaha | Nebraska | 68118 | United States |
| Peter Hyans | Berkeley Heights | New Jersey | 07922 | United States |
| Isaac Starker | Florham Park | New Jersey | 07932 | United States |
| Peter Hetzler | Little Silver | New Jersey | 07739 | United States |
| Marc Alan Drimmer | Princeton | New Jersey | 08540 | United States |
| Caroline Glicksman | Sea Girt | New Jersey | 08750 | United States |
| Lloyd Gayle | New York | New York | 10021 | United States |
| John Sherman | New York | New York | 10028 | United States |
| Tracy Pfeifer | New York | New York | 10028 | United States |
| Robert Jacobs | Port Jefferson Station | New York | 11776 | United States |
| John Decorato | Staten Island | New York | 10306 | United States |
| Raymond Isakov | Cleveland | Ohio | 44195 | United States |
| Craig Colville | Toledo | Ohio | 43615 | United States |
| Frank Barone | Toledo | Ohio | 43623 | United States |
| Derek Shadid | Oklahoma City | Oklahoma | 73134 | United States |
| Robert Hein | Oklahoma City | Oklahoma | 73134 | United States |
| Mark Jewell | Eugene | Oregon | 97401 | United States |
| John Lettieri | Spartanburg | South Carolina | 29303 | United States |
| Kristina D. O'Shaughnessy | Nashville | Tennessee | 37203 | United States |
| Patrick Maxwell | Nashville | Tennessee | 37212 | United States |
| William Carpenter | Dallas | Texas | 75246 | United States |
| Jeffrey Friedman | Houston | Texas | 77030 | United States |
| Natan Yaker | Plano | Texas | 75093 | United States |
| William Adams | University Park | Texas | 75205 | United States |
| Gloria Duda | McLean | Virginia | 22101 | United States |
| Gavin Dry | Bellevue | Washington | 98005 | United States |
| Allen Gabriel | Vancouver | Washington | 98664 | United States |
| FG002 | Reconstruction | Women who had breast reconstruction with NATRELLE® 410 implants. |
| FG003 | Revision-Reconstruction | Women who had revision of previous breast reconstruction with NATRELLE® 410 implants. |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Evaluable population was defined as all participants enrolled under this study protocol who received a NATRELLE® 410 X- or L-style device.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Augmentation | Women who had breast augmentation with NATRELLE® 410 implants. |
| BG001 | Revision-Augmentation | Women who had revision of previous breast augmentation with NATRELLE® 410 implants. |
| BG002 | Reconstruction | Women who had breast reconstruction with NATRELLE® 410 implants. |
| BG003 | Revision-Reconstruction | Women who had revision of previous breast reconstruction with NATRELLE® 410 implants. |
| BG004 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Number analyzed is the number of participants with available age data. | Mean | Full Range | years |
| |||||||||
| Sex: Female, Male | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percentage of Participants According to Investigator Satisfaction With Implants | The investigator rated their satisfaction with the participant's breast implant for each breast on a 5-point scale (1=Definitely dissatisfied, 2=Somewhat dissatisfied, 3=Neither satisfied or dissatisfied, 4=Somewhat satisfied, 5=Definitely satisfied). If there was a different response for the left and right breasts the worst response was used. The percentage of participants where the investigator responded: "Definitely satisfied" or "Somewhat satisfied" is reported. | Participants from the Evaluable population, all participants enrolled under this study protocol who received a NATRELLE® 410 X- or L-style device, with data available for analysis. | Posted | Number | percentage of participants | 5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015) |
|
|
| |||||||||||||||||||||||||||||||||||
| Primary | Percentage of Participants According to Participant Satisfaction With Implants | The participant rated their satisfaction with the breast implant for each breast on a 5-point scale (1=Definitely dissatisfied, 2=Somewhat dissatisfied, 3=Neither satisfied or dissatisfied, 4=Somewhat satisfied, 5=Definitely satisfied). If there was a different response for the left and right breasts the worst response was used. The percentage of participants who responded: "Definitely satisfied" or "Somewhat satisfied" is reported. | Participants from the Evaluable population, all participants enrolled under this study protocol who received a NATRELLE® 410 X- or L-style device, with data available for analysis. | Posted | Number | percentage of participants | 5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015) |
| |||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With Local Complications | Kaplan-Meier risk rates (estimation of the percentage of participants) of developing local complications is presented. Local complications collected in the study were: Asymmetry, Breast pain, Capsular contracture, Delayed wound healing, Fluid accumulation/seroma, Hematoma, Hypertrophic scarring/other abnormal scarring, Implant extrusion, Implant malposition, Implant palpability/visibility, Implant rupture, Infection, Redness, Skin rash, Swelling, Tissue/skin necrosis, Upper pole fullness, Wrinkling/rippling and Other complications . | Evaluable population was defined as all participants enrolled under this study protocol who received a NATRELLE® 410 X- or L-style device. | Posted | Number | 95% Confidence Interval | percentage of participants | 5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015) |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With Reoperations | Kaplan-Meier risk rates (estimation of the percentage of participants) of reoperation is reported. | Evaluable population was defined as all participants enrolled under this study protocol who received a NATRELLE® 410 X- or L-style device. | Posted | Number | 95% Confidence Interval | percentage of participants | 5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015) |
| ||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With Implant Removal With or Without Replacement | Kaplan-Meier risk rates (estimation of the percentage of participants) of implant removal with or without replacement is reported. | Evaluable population was defined as all participants enrolled under this study protocol who received a NATRELLE® 410 X- or L-style device. | Posted | Number | 95% Confidence Interval | percentage of participants | 5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015) |
|
5 years (followup after implantation that occurred between 06 May 2008 and 08 January 2015)
Adverse events were not collected in this study. Deaths are reported as Serious Adverse Events. Specific local complications were collected and are reported in the Outcome Measure section. Evaluable population.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Augmentation | Women who had breast augmentation with NATRELLE® 410 implants. | 0 | 278 | 0 | 0 | ||
| EG001 | Revision-Augmentation | Women who had revision of previous breast augmentation with NATRELLE® 410 implants. | 0 | 201 | 0 | 0 | ||
| EG002 | Reconstruction | Women who had breast reconstruction with NATRELLE® 410 implants. | 7 | 1,180 | 0 | 0 | ||
| EG003 | Revision-Reconstruction | Women who had revision of previous breast reconstruction with NATRELLE® 410 implants. | 1 | 225 | 0 | 0 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
| |||
| Pulmonary hypertension | Respiratory, thoracic and mediastinal disorders |
| |||
| Metastatic carcinoma to liver | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
| |||
| Recurrence of breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
| |||
| Liver cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
| |||
| Metastatic breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
Not provided
A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Therapeutic Area, Head | Allergan | 714-246-4500 | clinicaltrials@allergan.com |
|
|
| Somewhat satisfied |
|
| OG003 | Revision-Reconstruction | Women who had revision of previous breast reconstruction with NATRELLE® 410 implants. |
|
|
| OG003 | Revision-Reconstruction | Women who had revision of previous breast reconstruction with NATRELLE® 410 implants. |
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
|